Thanks for reminding me of these SEC filings. I guess we will have to disagree about the meaning of these.
The S-3 sales indicated in the 9/1 and 9/15 filings were sales of stocks to satisfy load obligations to Illiad to Cytdoyn.
As you have continually noted the outstanding (likely paid at this point) obligation of $28 million to Samsung Biologics, I am surprised that you have not applauded this sale of stock and retiring of this obligation.
The December sales, as has been made abundantly clear, were by M. Mulholland of shares granted to him as compensation by Cytodyn. I don't believe that any of us know (have you asked?) what his motivation was to sell these shares, but I would expect that he had a purpose for which he desired or need the money.
His being the CFO for Cytodyn, I believe he has a reasonable sense of his own finances.
I know that you are concerned about the impact of these conference calls and the movement of the stock price, but as it is currently around $6, I believe that we and the markets do not share your concerns about these stock sales from a few weeks and a few months ago.
I have not seen any SEC filings the last few days.
I have seen the details of the PR for the upcoming webcast tomorrow (Nearly here!!)
REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries
Management will provide an update on recent clinical and regulatory developments regarding COVID-19 clinical trials, along with other strategic priorities: 1) BLA/MAA submissions to Health Canada, MHRA, EMA, and US FDA 2) HIV prevention trial/monotherapy trial 3) Potential revenue from HIV and manufacturing forecast 4) HIV Cure - amfAR 5) EUA submission timelines to same four agencies for COVID-19, if CD12 Trial results are supportive of an EUA 6) Long-hauler clinical trial and potential data readout timelines 7) NASH trial and potential interim analysis timeline 8) Cancer trial Breakthrough Therapy designation potential timelines 9) GvHD trial status 10) Stroke/MS new trials in 2021 11) NASDAQ uplisting status
I know that the status of the NASDAQ uplisting has been another recurrent item of concern. Thankfully it is to be discussed tomorrow (I highlighted it for your benefit. It is item number 11. Last but not least IMO). No need for us to email questions about that matter.
Could you tell me which of the items to be discussed cause you the most concern so that we may conduct our due diligence and act appropriately The time is growing very short for us to act.
Market Data 
Markets 
AI
